140 related articles for article (PubMed ID: 37167784)
21. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
23. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Chen K; Man K; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q
Liver Transpl; 2014 Mar; 20(3):261-9. PubMed ID: 24376158
[TBL] [Abstract][Full Text] [Related]
24. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Decaens T; Duvoux C
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.
Su RY; Ling SB; Shan QN; Wei XY; Wang R; Jia CK; Zhuang L; Shen T; Ding LM; Xu ZD; Luo LB; Sun LB; Li GM; Fang TS; Jiang N; Zhang K; Su ZJ; Peng ZH; Lang R; Jiang T; He Q; Ye LS; Yang Y; He YT; Guo WZ; Lan LG; Sun XY; Chen D; Chen ZS; Zhou DW; Ye SJ; Ye QF; Tian M; Shi JH; Wang B; Liu J; Lu Q; Rao W; Cai JZ; Lv T; Yang JY; Wang PS; Zhong L; Ma JS; Li QG; Wu SD; Lu CJ; Lu CD; Zhang DH; Wang X; Li ZQ; Teng MJ; Li JJ; Jiang WT; Li JH; Zhang QB; Zhu NQ; Wang ZX; He K; Xia Q; Song SH; Fu ZR; Qiu W; Lv GY; Song RP; Wang JZ; Wang Z; Zhou J; Chen G; Zhao YP; Li L; Hu ZM; Luo QJ; Si ZZ; Xie B; He XS; Guo ZY; Zheng SS; Xu X
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):106-112. PubMed ID: 34583911
[TBL] [Abstract][Full Text] [Related]
26. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
27. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.
Vivarelli M; Risaliti A
World J Gastroenterol; 2011 Nov; 17(43):4741-6. PubMed ID: 22147974
[TBL] [Abstract][Full Text] [Related]
28. The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Yilmaz S; Ince V
J Gastrointest Cancer; 2021 Dec; 52(4):1350-1355. PubMed ID: 34611833
[TBL] [Abstract][Full Text] [Related]
29. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Welker MW; Bechstein WO; Zeuzem S; Trojan J
Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
31. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
32. Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population.
Wang P; Song W; Li H; Wang C; Shi B; Guo W; Zhong L
Tumour Biol; 2015 Sep; 36(10):7807-15. PubMed ID: 25944162
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
34. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
[TBL] [Abstract][Full Text] [Related]
35. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
Yanik EL; Chinnakotla S; Gustafson SK; Snyder JJ; Israni AK; Segev DL; Engels EA
Liver Transpl; 2016 May; 22(5):627-34. PubMed ID: 26784951
[TBL] [Abstract][Full Text] [Related]
36. Rapamycin Nano-Micelle Ophthalmic Solution Reduces Corneal Allograft Rejection by Potentiating Myeloid-Derived Suppressor Cells' Function.
Wei C; Wang Y; Ma L; Wang X; Chi H; Zhang S; Liu T; Li Z; Xiang D; Dong Y; Wu X; Shi W; Gao H
Front Immunol; 2018; 9():2283. PubMed ID: 30349533
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
[TBL] [Abstract][Full Text] [Related]
38. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Schnitzbauer AA; Filmann N; Adam R; Bachellier P; Bechstein WO; Becker T; Bhoori S; Bilbao I; Brockmann J; Burra P; Chazoullières O; Cillo U; Colledan M; Duvoux C; Ganten TM; Gugenheim J; Heise M; van Hoek B; Jamieson N; de Jong KP; Klein CG; Klempnauer J; Kneteman N; Lerut J; Mäkisalo H; Mazzaferro V; Mirza DF; Nadalin S; Neuhaus P; Pageaux GP; Pinna AD; Pirenne J; Pratschke J; Powel J; Rentsch M; Rizell M; Rossi G; Rostaing L; Roy A; Scholz T; Settmacher U; Soliman T; Strasser S; Söderdahl G; Troisi RI; Turrión VS; Schlitt HJ; Geissler EK
Ann Surg; 2020 Nov; 272(5):855-862. PubMed ID: 32889867
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.
Menon KV; Hakeem AR; Heaton ND
Aliment Pharmacol Ther; 2013 Feb; 37(4):411-9. PubMed ID: 23278125
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.
Yang Z; Zhang L; Zhu H; Zhou K; Wang H; Wang Y; Su R; Guo D; Zhou L; Xu X; Song P; Zheng S; Xie H
J Cell Mol Med; 2021 Apr; 25(7):3511-3523. PubMed ID: 33713546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
